Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report

Novo Nordisk AS (NYSE:NVO) and Hims & Hers Health Inc. (NYSE:HIMS) have reportedly ended their legal dispute, with plans to sell Novo's weight-loss drug on Hims' telehealth platform. This partnership follows a previous agreement in 2025 that was terminated due to Hims promoting a compounded version of Novo's drug. Following the news, Hims' shares surged 39.77% in after-hours trading, while Novo Nordisk's shares rose 2.12%. The U.S. FDA is increasing scrutiny on copycat weight-loss drugs amid growing competition in the obesity drug market.